Stay updated on Nivolumab +/- Ipilimumab for Liver Cancer Clinical Trial
Sign up to get notified when there's something new on the Nivolumab +/- Ipilimumab for Liver Cancer Clinical Trial page.

Latest updates to the Nivolumab +/- Ipilimumab for Liver Cancer Clinical Trial page
- Check7 days agoChange DetectedThe page revision label was updated from v3.3.1 to v3.3.2; no study content or critical details were changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check14 days agoChange DetectedAdded a note that publications are automatically filled from PubMed and may not be about the study, and updated the revision to v3.3.1. Deleted wording stating that PubMed publications are automatically created by ClinicalTrials.gov with an identifier and may or may not be related to the study; revision updated from v3.2.0.SummaryDifference0.1%

- Check21 days agoChange DetectedThe page no longer includes the government funding operating status notice in the footer; this change does not affect study details such as eligibility criteria, endpoints, or enrollment.SummaryDifference0.4%

- Check28 days agoNo Change Detected
- Check35 days agoChange DetectedMinor UI/layout adjustments and some wording tweaks across sections like Study Overview and Study Plan; core content such as the study title, eligibility criteria, interventions, endpoints, and enrollment remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check64 days agoChange DetectedUpgraded to version v3.2.0 with a funding-status notice about operational limitations; v3.1.0 was removed. Indicates a maintenance/availability update rather than new content.SummaryDifference3%

- Check71 days agoChange DetectedMajor addition of immunology-related terms and a version upgrade to v3.1.0; removal of the previous version v3.0.2.SummaryDifference0.9%

Stay in the know with updates to Nivolumab +/- Ipilimumab for Liver Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab +/- Ipilimumab for Liver Cancer Clinical Trial page.